To the Editor NOR-DRUM Part A1 is the first randomized clinical trial to investigate the role of proactive therapeutic drug monitoring (TDM) during initiation of infliximab therapy in adults with various immune-mediated inflammatory disorders. The primary end point of clinical remission at week 30 did not differ significantly between the proactive TDM and standard therapy groups. The subset of patients with inflammatory bowel disease (IBD) had a similar outcome for the primary study end point as well as for numerous secondary outcomes.1
Papamichail K, Dubinsky MC, Cheifetz AS. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases. JAMA. 2021;326(11):1067–1068. doi:10.1001/jama.2021.11477
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: